Horizon therapeutics south san francisco12/12/2023 “Horizon brings nearly a decade of rare disease expertise to the Bay Area,” said Mike Guerra, president and chief executive officer of the California Life Sciences Association. Horizon plans to add new positions in bioanalysis, clinical research, pharmacology, manufacturing and business development during the next year. “We look forward to exploring new partnerships in the South San Francisco biotech hub, and tapping into the wealth of talent in the area’s biotech and academic communities, as we develop new solutions to address needs in rare diseases and beyond.” “This new facility will allow us to function more seamlessly and efficiently as we expand our pipeline,” said Srini Ramanathan Ph.D., vice president, development sciences and site head for the South San Francisco, Horizon. “We are excited to join the thriving life sciences community of South San Francisco, allowing us the opportunity to connect to newer technologies, leading academic institutions and the dynamic scientific area at large.” “This is a significant step as we continue to grow our manufacturing and R&D capability to address patient needs through the development of groundbreaking therapies,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development and other R&D functions. Horizon Therapeutics plc (Nasdaq: HZNP) announced today the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |